Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing–Remitting Multiple Sclerosis

Fingolimod and natalizumab are approved disease-modifying drugs in relapsing–remitting multiple sclerosis (RRMS). The two drugs have different modes of action and may therefore influence different aspects of MS-related tissue damage. In this retrospective cohort study, we longitudinally compared pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Grahl, S., Bussas, M., Wiestler, B., Eichinger, P., Gaser, C., Kirschke, J., Zimmer, C., Berthele, A., Hemmer, B., Mühlau, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804113/
https://www.ncbi.nlm.nih.gov/pubmed/34561843
http://dx.doi.org/10.1007/s13311-021-01118-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804113/
https://www.ncbi.nlm.nih.gov/pubmed/34561843
http://dx.doi.org/10.1007/s13311-021-01118-2

Ejemplares similares